Literature DB >> 19075607

Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (i/r) injury: useful techniques for cardiovascular drug discovery.

Ramesh Vidavalur1, Snehasikta Swarnakar, Mahesh Thirunavukkarasu, Samson Mathews Samuel, Nilanjana Maulik.   

Abstract

The last few decades have seen significant advancement in the therapy of Ischemic Heart Diseases (IHD). This is a direct outcome of the increasing knowledge of the molecular mechanisms involved during an ischemic insult of the myocardium. Even then there is still a major unmet need for better strategies or drug therapies to reduce ventricular remodeling and improve post-ischemic myocardial function. The ex-vivo isolated working heart model and the in vivo myocardial infarction model are the best known techniques to elucidate the contribution of a drug therapy to confer cardioprotection in the event of an ischemic insult/reperfusion. Our review aims to provide an insight into the state of the art techniques that lay the foundations for cardiovascular drug discovery and present the prospects for further development from a preclinical perspective. The first section of the review provides an overview of the rat/mouse ex-vivo and in vivo models of myocardial ischemia. The following section will then present various applications of these clinically relevant models in characterizing cardiac functions, screening for drugs and identifying the drug induced changes in cardiac functions. Finally the role of these models in drug development is discussed with respect to functional relevance of drug treatment on heart rate, aortic flow, coronary flow, infarct size and the mechanisms by which these drugs promote myocardial protection. This review may serve as a basic knowledge for researchers who intend to study the efficacy of a drug in the treatment of ischemic heart diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075607     DOI: 10.2174/157016308786733555

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  15 in total

1.  Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice.

Authors:  Ram Sudheer Adluri; Mahesh Thirunavukkarasu; Lijun Zhan; Yuzo Akita; Samson Mathews Samuel; Hajime Otani; Ye-Shih Ho; Gautam Maulik; Nilanjana Maulik
Journal:  J Mol Cell Cardiol       Date:  2010-11-11       Impact factor: 5.000

Review 2.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

Review 3.  Model systems for cardiovascular regenerative biology.

Authors:  Jessica C Garbern; Christine L Mummery; Richard T Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

4.  Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Authors:  Yazhini Ravi; Karuppaiyah Selvendiran; Sarath Meduru; Lucas Citro; Shan Naidu; Mahmood Khan; Brian K Rivera; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

Review 5.  Ischemic ventricular arrhythmias: experimental models and their clinical relevance.

Authors:  José M Di Diego; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-07-06       Impact factor: 6.343

6.  Preconditioning by subinotropic doses of ouabain in the Langendorff perfused rabbit heart.

Authors:  Eric E Morgan; Zhichuan Li; Cory Stebal; Aude Belliard; Glen Tennyson; Bijan Salari; Keith D Garlid; Sandrine V Pierre
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

7.  Inhibition of serine/threonine protein phosphatase PP1 protects cardiomyocytes from tunicamycin-induced apoptosis and I/R through the upregulation of p-eIF2α.

Authors:  Chun-Lei Liu; Yun-Yun He; Xin Li; Rui-Jun Li; Kun-Lun He; Li-Li Wang
Journal:  Int J Mol Med       Date:  2013-12-23       Impact factor: 4.101

8.  Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36.

Authors:  Lokesh K Bhatt; Jyotika Bansal; Poonam Piplani; S L Bodhankar; A Veeranjaneyulu
Journal:  J Exp Pharmacol       Date:  2010-02-11

Review 9.  Acute Stress Decreases but Chronic Stress Increases Myocardial Sensitivity to Ischemic Injury in Rodents.

Authors:  Eric D Eisenmann; Boyd R Rorabaugh; Phillip R Zoladz
Journal:  Front Psychiatry       Date:  2016-04-25       Impact factor: 4.157

10.  A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil.

Authors:  Mariann Bombicz; Daniel Priksz; Balazs Varga; Andrea Kurucz; Attila Kertész; Akos Takacs; Aniko Posa; Rita Kiss; Zoltan Szilvassy; Bela Juhasz
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.